Business Context and Reporting Period
This Form 8-K Current Report was filed by IRADIMED CORPORATION on June 9, 2016. The report addresses a regulatory development concerning the Company's MRidium 3860+ MRI compatible IV infusion pump.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on a regulatory event and does not contain financial statement data.
Material Changes
The primary material change reported is the U.S. Food and Drug Administration's (FDA) written response to the Company's appeal regarding the 510(k) application for the MRidium 3860+ infusion pump. The FDA reinstated the application, which had previously been determined not substantially equivalent to its predicate device.
Guidance, Outlook, and Management Commentary
- Regulatory Status: The FDA granted the Company an additional 180 days to implement specified changes to the infusion pump's user interface messages.
- Required Actions: The Company must revise messages to clarify the status of the Dose Error Reduction System (active or inactive) and better describe over and under range indications.
- Testing Requirements: The FDA explicitly stated that no additional human factors usability testing is required.
- Management Plan: The Company intends to revise the identified messages consistent with FDA recommendations and submit the required information within the 180-day window.
Investor Verification Checklist
- Verify the specific timeline for the 180-day submission period ending in December 2016.
- Confirm the technical details of the message revisions required for the Dose Error Reduction System.
- Monitor future filings for the submission of the revised 510(k) information and the final FDA clearance decision.
- Review the full text of the press release included as Exhibit 99.1 for additional context.